glp 1 drugs compounding pharmacy FDA Intensifies Crackdown on GLP-1 FDA Moves to Permanently Close
Description
For others, it may be lowering the dose to reduce side effects, cost, or treatment burden

10.1111/j.1369-1600.2006.00012.x 53 SayehmiriF.SamadianM.MohamadkhaniA.TafakhoriA.HaghighatS.RahmatianA.et al (2022)

[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Lee PH, Stockton MD, Franks AS

Gut-brain axis and addictive disorders: a review with focus on alcohol and drugs of abuse

For researchers and institutions: Mandate sex- and hormone-state reporting in trials of diabetes therapies and require pre-specified subgroup analyses

For example, participants in the trials reported side effects that were generally consistent with previous studies, such as gastrointestinal symptoms, which are one of the main reasons that can lead to discontinuation of the drugs
